In-person registrations are now closed as the event has reached the threshold for onsite participation. We thank you for your interest and apologize for any inconvenience.

Where: József Antall (JAN), room 6Q1

When: Tuesday 29 November 2022, 15:00 -17:00

The registration is closed. If you wish join the event online, please send your request to:


15:00 - 15:10Welcome address

Dr Stelios Kympouropoulos, MEP
15:10 – 15:25The State of the ATMP sector in Europe

Tim Hunt, Chief Executive Officer, Alliance for Regenerative Medicine
15:25 – 15:40Testimonial from the first pediatric patient cured with CAR-T therapy

Emily Whitehead & Tom Whitehead, Emily Whitehead Foundation
15:40 – 15:55EU initiatives of relevance to the ATMP sector

Sylvain Giraud, Head of Unit ‘Medical Products: Quality, Safety, Innovation’, DG Sante, European Commission
15:55 – 16:55Panel discussion: How to improve patient access to ATMPs in Europe?

Patrick Celis, Scientific Administrator, Committee for Advanced Therapies, European Medicines Agency
Lucy Ellerker, Patient Advocate
Simone Boselli, Director of Public Affairs, EURORDIS Rare Disease Europe
Susana Solís Perez, MEP
Chris Vann, Chief Operating Officer at Autolus, and Member of the Alliance for Regenerative Medicine’s Board
16:55 – 17:00Concluding remarks

Dr Miguel Forte, President-Elect of the International Society for Cell & Gene Therapy, and Member of the Alliance for Regenerative Medicine’s Board

Data Privacy
The Alliance for Regenerative Medicine is committed to data privacy and protecting your personal information. By submitting your email address during the conference registration process, you agree that the Alliance for Regenerative Medicine may send you conference-related information. A valid email address is required for all registrations. The Alliance for Regenerative Medicine may disclose your personal data to third-party service providers engaged to assist in the planning of the conference. The information you provide when registering may be shared with those parties, and the treatment of such information is further subject to the privacy policies of those parties.